Abstract B134: The p38MAPK inhibitor LY2228820 dimesylate, in combination with cytotoxic agents, displays strong antitumor activity in human glioblastoma, multiple myeloma, and other mouse xenograft models.
Susan E. Pratt(Eli Lilly (Spain)), Louis F. Stancato(Indiana Biosciences Research Institute), Nathan A. Brooks(Eli Lilly (United States)), Robert M. Campbell(Children's Health Queensland Hospital and Health Service), James J. Starling(Eli Lilly (Spain)), Raymond Gilmour(Eli Lilly (Spain)), Michele Dowless(Eli Lilly (United States)), Steve F. Parsons(Eli Lilly (United States)), Wayne Blosser(Eli Lilly (United States))
Cited by 0
Related Papers
Histone Modifications and Cancer
|Cold Spring Harbor Perspectives in Biology|2016|1.1k
Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer
|The Journal of Urology|2019|190
100 years of Bacillus Calmette–Guérin immunotherapy: from cattle to COVID-19
|Nature Reviews Urology|2021|154
Cancer epigenetics drug discovery and development: the challenge of hitting the mark
|Journal of Clinical Investigation|2014|149
Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
|Molecular Cancer Therapeutics|2013|121